Recombinant lentivirus has become a vector of choice for many gene-modified cell therapies, including several FDA-approved cell therapies, due to the broad tropism and long-term, stable gene expression in non-dividing cells. The safety and efficacy of lentiviral-based therapies depends greatly on optimized and controlled lentiviral production. Downstream purification of lentiviral particles presents unique challenges, and robust analytics are critical to verify both the recovery and infectivity of the purified product.
In this webinar we present an overview of challenges and newly developed solutions for robust lentiviral purification and rapid analytical methods for titer determination and impurity quantification. Details of a new affinity chromatography resin, based on CaptureSelect technology, to purify VSV-G pseudotyped lentivirus, as well as two q-PCR based genomic and proviral infectious titer assays will be discussed.
Attendees will learn about: